Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.

Saelen MG, Ree AH, Kristian A, Fleten KG, Furre T, Hektoen HH, Flatmark K.

Radiat Oncol. 2012 Sep 27;7:165. doi: 10.1186/1748-717X-7-165.

2.

Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.

Folkvord S, Ree AH, Furre T, Halvorsen T, Flatmark K.

Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):546-52. doi: 10.1016/j.ijrobp.2009.01.068.

PMID:
19427556
3.

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.

Di Gennaro E, Piro G, Chianese MI, Franco R, Di Cintio A, Moccia T, Luciano A, de Ruggiero I, Bruzzese F, Avallone A, Arra C, Budillon A.

Br J Cancer. 2010 Nov 23;103(11):1680-91. doi: 10.1038/sj.bjc.6605969. Epub 2010 Nov 2.

4.

Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.

Morelli MP, Tentler JJ, Kulikowski GN, Tan AC, Bradshaw-Pierce EL, Pitts TM, Brown AM, Nallapareddy S, Arcaroli JJ, Serkova NJ, Hidalgo M, Ciardiello F, Eckhardt SG.

Clin Cancer Res. 2012 Feb 15;18(4):1051-62. doi: 10.1158/1078-0432.CCR-11-1507. Epub 2011 Dec 15.

5.

Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.

Yoo C, Ryu MH, Na YS, Ryoo BY, Lee CW, Maeng J, Kim SY, Koo DH, Park I, Kang YK.

Invest New Drugs. 2014 Apr;32(2):271-8. doi: 10.1007/s10637-013-9983-2. Epub 2013 May 28.

PMID:
23712440
6.

Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.

Ouchi KF, Yanagisawa M, Sekiguchi F, Tanaka Y.

Cancer Chemother Pharmacol. 2006 May;57(5):693-702. Epub 2005 Dec 16.

PMID:
16362295
7.

Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.

Lautz TB, Naiditch JA, Clark S, Chu F, Madonna MB.

J Pediatr Surg. 2012 Jun;47(6):1267-71. doi: 10.1016/j.jpedsurg.2012.03.039.

PMID:
22703804
8.

Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts.

Baschnagel A, Russo A, Burgan WE, Carter D, Beam K, Palmieri D, Steeg PS, Tofilon P, Camphausen K.

Mol Cancer Ther. 2009 Jun;8(6):1589-95. doi: 10.1158/1535-7163.MCT-09-0038. Epub 2009 Jun 9.

9.
10.

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.

He S, Smith DL, Sequeira M, Sang J, Bates RC, Proia DA.

Invest New Drugs. 2014 Aug;32(4):577-86. doi: 10.1007/s10637-014-0095-4. Epub 2014 Apr 1.

11.

Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts.

Kolinsky K, Zhang YE, Dugan U, Heimbrook D, Packman K, Higgins B.

Anticancer Res. 2009 Jan;29(1):91-8.

12.

SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.

Novotny-Diermayr V, Sangthongpitag K, Hu CY, Wu X, Sausgruber N, Yeo P, Greicius G, Pettersson S, Liang AL, Loh YK, Bonday Z, Goh KC, Hentze H, Hart S, Wang H, Ethirajulu K, Wood JM.

Mol Cancer Ther. 2010 Mar;9(3):642-52. doi: 10.1158/1535-7163.MCT-09-0689. Epub 2010 Mar 2.

13.

Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.

Mueller S, Yang X, Sottero TL, Gragg A, Prasad G, Polley MY, Weiss WA, Matthay KK, Davidoff AM, DuBois SG, Haas-Kogan DA.

Cancer Lett. 2011 Jul 28;306(2):223-9. doi: 10.1016/j.canlet.2011.03.010. Epub 2011 Apr 16.

14.

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

Russo SM, Tepper JE, Baldwin AS Jr, Liu R, Adams J, Elliott P, Cusack JC Jr.

Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):183-93.

PMID:
11316563
15.

Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis.

An X, Lin X, Wang FH, Goodman K, Cai PQ, Kong LH, Fang YJ, Gao YH, Lin JZ, Wan DS, Pan ZZ, Ding PR.

Eur J Cancer. 2013 Mar;49(4):843-51. doi: 10.1016/j.ejca.2012.09.026. Epub 2012 Oct 11.

PMID:
23063351
16.

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.

Millward M, Price T, Townsend A, Sweeney C, Spencer A, Sukumaran S, Longenecker A, Lee L, Lay A, Sharma G, Gemmill RM, Drabkin HA, Lloyd GK, Neuteboom ST, McConkey DJ, Palladino MA, Spear MA.

Invest New Drugs. 2012 Dec;30(6):2303-17. doi: 10.1007/s10637-011-9766-6. Epub 2011 Nov 12.

PMID:
22080430
17.

Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine.

Prasad S, Yadav VR, Sung B, Reuter S, Kannappan R, Deorukhkar A, Diagaradjane P, Wei C, Baladandayuthapani V, Krishnan S, Guha S, Aggarwal BB.

Clin Cancer Res. 2012 Sep 15;18(18):4942-53. doi: 10.1158/1078-0432.CCR-11-2805. Epub 2012 Jul 25.

18.

Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?

Folkvord S, Flatmark K, Seierstad T, Røe K, Rasmussen H, Ree AH.

Radiother Oncol. 2008 Mar;86(3):428-34. Epub 2007 Nov 19.

PMID:
18006097
19.

In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models.

Kolinsky K, Shen BQ, Zhang YE, Kohles J, Dugan U, Zioncheck TF, Heimbrook D, Packman K, Higgins B.

Mol Cancer Ther. 2009 Jan;8(1):75-82. doi: 10.1158/1535-7163.MCT-08-0596.

20.

Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.

Jin K, Lan H, Xie B, He K, Xu Z, Li G, Han N, Teng L, Cao F.

Cancer Biol Ther. 2012 Jul;13(9):737-44. Epub 2012 May 23.

PMID:
22617773

Supplemental Content

Support Center